ABOUT - Management Team

Mark B. Benjamin President & Chief Executive Officer
Mark comes to Galenea with 16 years of industry experience, 13 in business development. He was most recently the Chief Business Officer of Nura Inc., a neuroscience drug discovery company founded by 2004 Nobel laureate Dr. Linda Buck, which was acquired by Omeros Inc. in 2006. In previous positions, he served as Vice President of Global Business Development for Manteia SA, a Swiss-based subsidiary of Serono SA (now Merck KGaA) and was the senior business development executive at Rosetta Inpharmatics, a company founded by a team that included 2001 Nobel laureate Leland Hartwell. Rosetta was acquired by Merck & Company in 2001. Mark received a first class B.Sc. degree with honors from the University of London and a D.Sc. degree in Cancer Biology from Harvard University.

David J. Gerber Vice President, CNS Research
David is a founding scientist at Galenea. He has more than ten years of experience in CNS research primarily in the areas of psychiatric disease biology, molecular and behavioral neuroscience and mouse molecular genetics. Recently, his research has focused on the genetics of schizophrenia and particularly on the involvement of calcineurin dysfunction in schizophrenia pathogenesis. David received a bachelor's degree in mathematics from MIT in 1987 and a Ph.D. in biology from MIT in 1996. David pursued his postdoctoral research in Dr. Susumu Tonegawa's laboratory at the Picower Institute for Learning and Memory at MIT prior to joining Galenea in 2004.

Graham Johnson Drug Discovery
Graham has worked as a senior medicinal chemist for both large pharmaceutical and small biotech companies including Hoechst, Parke-Davis, Bristol-Myers Squibb and Rib-X. During his 30 year career, Graham has gathered extensive experience in the areas of central nervous system disorders (CNS), genitourinary diseases and antibacterials and has been involved in the discovery and development of a diverse array of drugs that have reached advanced preclinical and clinical evaluation. These compounds include MaxiPostTM, Radezolid and Delafloxacin as well as compounds for calcium dysregulation, migraine, Alzheimer's disease, sleep disorders, circadian dysregulation, obesity, genitourinary diseases and virology. Graham received his B.Sc. (Chemistry) and Ph.D. degrees from Heriot-Watt University, Edinburgh and was then awarded a Fulbright Senior Fellowship for study in the U.S.

David Neafus Chief Financial Officer
Prior to joining Galenea, David, over the previous 14 years, has operated his own consulting firm providing executive services, specializing in interim executive management, IPOs, turnarounds, strategic analysis, and mergers and acquisitions. Previous clients include GlycoFi, where as CFO David helped the company complete its $400 Million acquisition by Merck, Alnylam Pharmaceuticals, Inc. where as Vice President of Finance, David led the company to a successful IPO, Infinity Pharmaceuticals where David served as Vice President Finance and Administration and Millennium Pharmaceuticals where he served as Corporate Controller. Prior to running his own consulting firm, David was an auditor at KPMG for 4½ years. David received his bachelor's degree in accounting from the University of Minnesota, and his MBA from Bentley College. He is also a certified public accountant.

Lisa R. Paborsky Corporate Development
Lisa is a corporate development professional with a strong scientific background and 20 years of experience in the biotech industry. Previously, Lisa worked at Ensemble Discovery and at Biogen Idec, where she played a central role in M & A, partnerships and research collaborations, completing numerous deals including the oncology partnership that ultimately led to the merger between Biogen and Idec. Lisa also spent several years at Gilead Sciences, initially as a Group Leader in discovery research and then transitioning into corporate development. Lisa received her Ph.D. in Cancer Biology from Stanford University and performed post-doctoral research in the cardiovascular group at Genentech.

Adam Rosenberg Corporate Development
Adam has a significant amount of leadership and transactional experience in the life sciences sector, and began working with Galenea in early 2011. Since 2009, Adam has primarily advised emerging companies as a director and consultant, including co-founding Clean Membranes, a materials company based on technology licensed from MIT. Previously, he was co-founder and CEO of Link Medicine, a biotechnology company focused on discovering and developing novel neurodegenerative therapies. He also helped to launch and build the boutique transactional life sciences law firm Faber Daeufer & Rosenberg PC. Adam received a B.A. from Whittier College, magna cum laude, and a J.D. from The University of Virginia School of Law.